Viatris Inc. (VTRS), valued at a market cap of $14.6 billion, is a global pharmaceutical and healthcare company formed in November 2020. Headquartered in Canonsburg, Pennsylvania, it develops, manufactures and distributes a broad portfolio of generic, branded, complex generic and biosimilar medicines across more than 165 countries and territories, supplying high-quality medicines to roughly 1 billion patients globally each year. The global healthcare giant is expected to announce its fiscal 2025 fourth-q ...

Core Insights - Viatris has launched Inpefa (sotagliflozin) in the UAE, marking the first commercialization of this treatment in its territories, with plans for future launches in multiple countries to expand access outside the U.S. and Europe [1][3] Product Overview - Inpefa is the first and only dual SGLT1/2 inhibitor approved for heart failure treatment, aimed at reducing cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors [2][6] - The approval of Inpefa is based on two pivotal Phase 3 trials, SOLOIST-WHF and SCORED, which enrolled over 11,800 patients globally, demonstrating significant reductions in major cardiovascular events [3][5] Clinical Efficacy - In the SOLOIST-WHF trial, Inpefa reduced the composite risk of heart failure hospitalization, urgent visits, and cardiovascular death by 33% compared to placebo, with benefits increasing to 51% when initiated prior to discharge [3] - In the SCORED trial, Inpefa achieved a 25% reduction in the same composite endpoint among patients with type 2 diabetes and chronic kidney disease [3] - The treatment also showed a 23% reduction in major adverse cardiovascular events (MACE), with significant reductions in myocardial infarction (32%) and stroke (34%) [3] Market Context - Heart failure is the leading cause of hospitalization globally, affecting over 64 million people, with substantial post-discharge mortality and readmission rates [4] - The 30-day post-discharge mortality rate is approximately 6.7%, with readmission rates averaging 13%, increasing to 23% mortality and 36% readmission at one year post-discharge [4] Company Strategy - Viatris aims to expand its innovative portfolio in cardiovascular diseases, leveraging its scientific leadership and commercial legacy [3][9] - The company has submitted regulatory filings for Inpefa in several countries, including Canada, Australia, and Mexico, and plans to broaden global submissions in the coming years [3][9]

Company Overview - Viatris operates as three distinct businesses: a global generics company, an established brands company with iconic brands, and an emerging innovative brands platform [3] Financial Performance - In the last 12 months, Viatris generated $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in adjusted EBITDA [4] - The company reported $2.2 billion in free cash flow and $2.32 billion in adjusted EBITDA [4] Global Reach - Viatris operates in 165 countries and offers 1,400 unique products [4] - The company provides medicine to over 1 billion people annually, highlighting its significant impact on global health [4]

Summary of Viatris Conference Call Company Overview - Viatris operates as three distinct businesses: a global generics company, an established brands company, and an emerging innovative brands platform [2][3] - The company reported $14.1 billion in revenue, $4.1 billion in EBITDA, and $2.2 billion in free cash flow over the last 12 months [2] Key Financial Highlights - Viatris delivered $14.1 billion in revenue and $4.1 billion in EBITDA [2] - Achieved $2.32 in adjusted EBITDA and $2.2 billion in free cash flow [2] - The company operates in 165 countries with 1,400 unique products, serving over 1 billion people annually [3] Strategic Developments - The company advanced its pipeline with five positive phase 3 readouts out of six [4] - Significant progress was made with Cenerimod, Selatogrel, and Lucerastat in their phase 3 programs [4] - Over $1 billion was returned to shareholders through dividends and share buybacks [4] - Conducted 60 regional business development deals to support the base business, particularly in Japan [4][5] Future Outlook - Anticipated high-value product launches in 2026, including Sotagliflozin, Phentolamine, and Effexor GAD [6][7] - The company expects to generate significant cash flow in 2026, with plans for continued shareholder returns and growth asset development [9] - A strategic review is expected to yield substantial savings and reinvestment opportunities [22][24] Market Dynamics - The company is focusing on the U.S. market for high-margin revenue-generating assets, while also revitalizing its portfolio in Japan [36] - The competitive landscape is favorable for acquiring assets in the $500 million-$1 billion revenue range, with less competition for these assets [20][21] Pipeline and Product Development - Positive phase 3 results for Cenerimod and Selatogrel are expected to lead to significant market opportunities [51][60] - Fast-Acting Meloxicam is positioned to address the opioid crisis in pain management, with a strong market potential [43][45] - Selatogrel aims to revolutionize acute myocardial infarction management, with a large patient population and significant unmet need [60][62] Challenges and Risks - Pricing pressures and policy adjustments are anticipated in the JANS business, along with generic competition in Japan [29] - The Indore facility's remediation is nearing completion, with limited expected volatility in 2026 numbers [30][32] Capital Allocation Strategy - The company plans a balanced approach to capital allocation, focusing on shareholder returns and business development [34] - Expected free cash flow of over $2 billion annually for the next five years [33] Conclusion - Viatris is positioned for sustainable growth with a strong pipeline, strategic acquisitions, and a focus on enhancing its core business while navigating market challenges [12][15]

44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1 Non-GAAP Financial Measures This presentation includes the presentation and discussion of certain financial information that differs from what is reported under accounting principles generally accepted in the United States ("U.S. GAAP"). These non-GAAP financial measures, including, but not limited to, adjusted EBITDA, free cash flow, free cash flow excluding transaction-related costs, and adjusted EPS, are presented in order to supplement inv ...

Core Insights - Viatris Inc. has appointed Lara Ramsburg as Chief People and Corporate Affairs Officer to enhance the company's culture and stakeholder communication strategies during its transformation efforts [1][5]. Company Overview - Viatris is a global healthcare company that aims to bridge the gap between generics and brand-name medications, providing access to high-quality medicines for approximately 1 billion patients annually [6]. Leadership and Experience - Lara Ramsburg brings over 25 years of experience in building effective cross-functional teams and strategic communication, having held various executive roles at Viatris and its legacy company, Mylan [2][3]. - In her new role, Ramsburg will oversee global talent, total rewards, employee experience, people solutions, and HR business partner teams, in addition to her existing responsibilities in Corporate Affairs [3]. Strategic Importance - The appointment of Ramsburg is seen as crucial for maintaining employee engagement, wellbeing, and growth as the company prepares for its next stage of growth [5].

Core Viewpoint - Viatris (VTRS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, with institutional investors using these estimates to determine fair value [4][6]. Company Performance and Investor Sentiment - The upgrade in Viatris' rating signifies an improvement in the company's underlying business, which is expected to positively influence its stock price [5][10]. - Over the past three months, the Zacks Consensus Estimate for Viatris has increased by 2.2%, with expected earnings of $2.32 per share for the fiscal year ending December 2025, unchanged from the previous year [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Viatris' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the top cheap stocks under $20, with recent regulatory milestones enhancing its investment appeal [1] Regulatory Milestones - The FDA approved Viatris' octreotide acetate for injectable suspension, a generic version of Sandostatin® LAR Depot, for treating acromegaly and certain types of diarrhea associated with tumors [1] - The FDA accepted the New Drug Application (NDA) for Viatris' investigational low dose estrogen weekly patch for contraception [2] - The FDA cleared the Investigational New Drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with plans for a Phase 1/2 clinical trial starting in H1 2026 [2] - The Japan Pharmaceuticals and Medical Devices Agency (PMDA) accepted the Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome, with plans to submit a J-NDA for narcolepsy by year-end [3] Company Overview - Viatris is a global healthcare company providing a wide range of pharmaceutical products across various therapeutic areas, including oncology, cardiovascular, dermatology, immunology, eye care, gastroenterology, and women's healthcare [4] - The company's operations are segmented into Developed Markets, Greater China, JANZ, and Emerging Markets [4]

Core Insights - Viatris Inc. (NASDAQ:VTRS) is recognized as one of the 14 Best Pharma Dividend Stocks to Buy in 2026 [1] - Barclays initiated coverage of Viatris with an Overweight rating and a price target of $15, indicating improving investor sentiment in the pharmaceutical sector [2] - Viatris announced a definitive agreement to sell its equity stake in Biocon Biologics Limited for a total consideration of $815 million, which includes $400 million in cash and $415 million in newly issued equity shares [3] Company Overview - Viatris Inc. is a global pharmaceutical company that offers a diverse range of medicines, including generics, branded drugs, biosimilars, OTC products, and active pharmaceutical ingredients (APIs) [4]

Industry Overview - Drug pricing has become a significant pressure point for pharmaceutical companies in the U.S. as efforts to reduce consumer costs at pharmacies intensify [1] - The U.S. is the largest single market for drugmakers, with prices often nearly three times higher than in other developed countries, leading to a heavy reliance on American sales for revenue [2] - The Most Favored Nations pricing model proposed by Donald Trump aims to tie U.S. drug prices to the lowest levels paid by other wealthy countries, which could have a substantial impact on pharmaceutical companies' financials if widely implemented [3][4] Market Performance - The S&P 500 Health Care sector has increased by over 13% this year, with health-care companies leading in earnings beats during the third quarter of 2025, marking the strongest performance in over four years [5] - Analysts suggest that as drug pricing uncertainty begins to ease, attention will shift to how pharmaceutical companies adapt to the changing landscape [5] Company Highlights Viatris Inc. (NASDAQ:VTRS) - Viatris has a dividend yield of 3.87% and is among the best dividend stocks in the pharmaceutical sector [11] - Barclays initiated coverage of Viatris with an Overweight rating and a $15 price target, noting improving investor sentiment and easing pricing pressure [12] - Viatris announced a deal to sell its equity stake in Biocon Biologics for $815 million, which includes $400 million in cash and $415 million in equity shares, aimed at enhancing its portfolio and market access [13] Gilead Sciences, Inc. (NASDAQ:GILD) - Gilead has a dividend yield of 2.54% and is recognized as a strong dividend stock [15] - The company entered a three-year agreement with the U.S. government to lower drug costs, reinforcing its commitment to U.S. innovation and affordability [16] - Gilead plans to invest $32 billion in U.S.-based manufacturing and R&D over the next five years, expecting to generate $43 billion in economic value and create over 3,000 jobs [17] Amgen Inc. (NASDAQ:AMGN) - Amgen has a dividend yield of 3.05% and has outperformed the broader market, with its stock up more than 27% since the start of 2025 [19] - The company reported a 12% revenue increase to $9.6 billion in the third quarter, driven by strong sales of key products like Repatha and Tezspire, both up 40% year-over-year [20] - Amgen has consistently raised its dividend since 2011, with a forward yield of about 3%, significantly higher than the S&P 500 average of 1.2% [22]